Gene interactions and pathways from curated databases and text-mining
Cardiovasc Drugs Ther 1999, PMID: 10372232

Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo.

Myllärniemi, M; Frösen, J; Calderón Ramirez, L G; Buchdunger, E; Lemström, K; Häyry, P

The long-term success of coronary angioplasty is limited by restonosis. This study was undertaken to investigate whether and to what extent the enhanced proliferative response observed in a balloon reinjury model of rat aorta is regulated by the PDGF receptor (PDGF-R). Balloon injury was performed to 14-day-old pre-existing neointimal lesion in rat aorta. PDGF receptor and ligand immunoreactivity were measured at several time points after the first and second injury, and PDGF-R signaling was blocked with a selective inhibitor of PDGF-R tyrosine kinase. In the neointima, after repeated injury, upregulation of PDGF-AA was seen to coincide with a prompt proliferative response of smooth muscle cells (SMC). Administration of the PDGF-R tyrosine kinase inhibitor in vivo, tested and found to inhibit the proliferation of SMC induced by PDGF-AA and PDGF-BB, but not by IGF-1, EGF, or bFGF, resulted in a 60% reduction in the absolute number and percentage of BrdU + cells after the second balloon injury to pre-existing neointima, but had no significant effect on proliferation after the first injury. Endpoint lesion area was reduced by 50% in the treated group at 14 days after the second injury. The results suggest that systemic administration of a tyrosine kinase inhibitor specific for the PDGF-R can be useful in the prevention of restenosis.

Document information provided by NCBI PubMed

Text Mining Data

SMC → EGF: " Administration of the PDGF-R tyrosine kinase inhibitor in vivo, tested and found to inhibit the proliferation of SMC induced by PDGF-AA and PDGF-BB, but not by IGF-1, EGF , or bFGF, resulted in a 60 % reduction in the absolute number and percentage of BrdU + cells after the second balloon injury to pre existing neointima, but had no significant effect on proliferation after the first injury "

SMC → bFGF: " Administration of the PDGF-R tyrosine kinase inhibitor in vivo, tested and found to inhibit the proliferation of SMC induced by PDGF-AA and PDGF-BB, but not by IGF-1, EGF, or bFGF , resulted in a 60 % reduction in the absolute number and percentage of BrdU + cells after the second balloon injury to pre existing neointima, but had no significant effect on proliferation after the first injury "

SMC → IGF-1: " Administration of the PDGF-R tyrosine kinase inhibitor in vivo, tested and found to inhibit the proliferation of SMC induced by PDGF-AA and PDGF-BB, but not by IGF-1 , EGF, or bFGF, resulted in a 60 % reduction in the absolute number and percentage of BrdU + cells after the second balloon injury to pre existing neointima, but had no significant effect on proliferation after the first injury "

SMC → PDGF-AA: " Administration of the PDGF-R tyrosine kinase inhibitor in vivo, tested and found to inhibit the proliferation of SMC induced by PDGF-AA and PDGF-BB, but not by IGF-1, EGF, or bFGF, resulted in a 60 % reduction in the absolute number and percentage of BrdU + cells after the second balloon injury to pre existing neointima, but had no significant effect on proliferation after the first injury "

SMC → PDGF-BB: " Administration of the PDGF-R tyrosine kinase inhibitor in vivo, tested and found to inhibit the proliferation of SMC induced by PDGF-AA and PDGF-BB , but not by IGF-1, EGF, or bFGF, resulted in a 60 % reduction in the absolute number and percentage of BrdU + cells after the second balloon injury to pre existing neointima, but had no significant effect on proliferation after the first injury "

Manually curated Databases

No curated data.